CVS up +0.43% percent Today $CVS High is at 89.62 and the

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
CVS up +0.43% percent Today $CVS High is at 89.62 and the Low 89.13 with current volume of 497,612.

Recent News posted below.

CVS Corp CVS other info.
http://investorshangout.com/CVS-Health-Corp-CVS-50666/

CVS CVS Corp Recent Headline News

Post Earnings Update: CVS Caremark Has Climbed 4.3% Higher in Past Week (CVS)
Comtex SmarTrend(R) - 52 mins ago
A week ago on November 4th, 2014 CVS Caremark (NYSE:CVS) reported earnings and analysts, on average, expected earnings of $1.13 on sales of $34.7 billion. The company actually reported EPS of $1.15 on sales of $35.0 billion, beating EPS estimates by $0.02 and beating revenue estimates by $285.0 million. Shares of CVS Caremark have climbed from $85.47 to $89.13, representing a gain of 4.3% since the company reported earnings 13 days ago.
CVS: 89.79 (+0.66)

Today's Top Performers In Services
at The Street - 2 hrs 6 mins ago
TheStreet highlights 3 stocks pushing the services sector higher today.
EBAY: 54.99 (+0.63), CVS: 89.79 (+0.66), LOW: 58.79 (+0.21)

How Apple Pay Can Help Mobile Transactions Soar by 2017
at The Street - Mon Nov 17, 9:17AM CST
As digital wallets and mobile payments become more prevalent, transactions on smartphones are expected to soar by 2017.
FB: 74.17 (-0.71), WMT: 83.56 (+0.60), CVS: 89.80 (+0.67), GOOGL: 546.72 (-8.47), AAPL: 113.96 (-0.22)

How Starbucks Could Take On Apple In Mobile Payments
at Investor's Business Daily - Mon Nov 17, 7:02AM CST
Starbucks (SBUX) customers are a loyal bunch -- loyal enough to protest the departure of their beloved eggnog latte, prompting the coffee chain to revive the seasonal favorite, and loyal enough to make the company the No. 1 most-expensed restaurant...
SBUX: 77.91 (-0.21), EBAY: 54.99 (+0.63), CVS: 89.80 (+0.67), WMT: 83.56 (+0.60), GOOGL: 546.72 (-8.47), AAPL: 113.96 (-0.22), RAD: 5.46 (-0.07)

Dividend Contenders: 26 Increases Expected In The Next 11 Weeks
David Fish - at Seeking Alpha - Mon Nov 17, 6:36AM CST

RGCO: 21.84 (-0.06), ROP: 156.76 (-0.49), SEIC: 39.01 (-0.26), NKE: 95.82 (+0.32), SJI: 56.53 (-0.07), AEL: 27.03 (-0.17), YORW: 21.34 (+0.11), ECL: 112.48 (+0.07), SYK: 88.48 (+0.48), AXS: 49.56 (-0.26), TGP: 38.76 (+0.66), JJSF: 103.15 (+0.40), GGG: 79.20 (+0.68), NWFL: 28.80 (-0.26), CVS: 89.80 (+0.67), UBA: 21.85 (-0.01), ERIE: 84.49 (-0.22), ANDE: 54.18 (-0.27), EIX: 62.56 (+0.80), LG: 50.34 (+0.22), LNT: 61.85 (+0.08), VGR: 21.32 (-0.08)

CVS Caremark Has Returned 14.7% Since SmarTrend Recommendation (CVS)
Comtex SmarTrend(R) - Fri Nov 14, 9:22AM CST
SmarTrend identified an Uptrend for CVS Caremark (NYSE:CVS) on July 24th, 2014 at $78.59. In approximately 4 months, CVS Caremark has returned 14.68% as of today's recent price of $90.12.
CVS: 89.80 (+0.67)

Why Rite Aid Will Retest $9
Brian Nichols - at Seeking Alpha - Thu Nov 13, 3:08PM CST

CVS: 89.80 (+0.67), WAG: 66.32 (-0.61), RAD: 5.46 (-0.07)

CVS Health Introduces Robust Consumer Education Resources for Upcoming Health Insurance Marketplace Open Enrollment
PR Newswire - Thu Nov 13, 10:30AM CST
CVS Health (NYSE: CVS) today announced a robust educational effort to increase its customers' understanding of available insurance options during the upcoming Affordable Care Act (ACA) Health Insurance Marketplace open enrollment period of November 15, 2014 to February 15, 2015. CVS Health is partnering with numerous health insurers offering coverage on the Marketplace to conduct health insurance education events in CVS/pharmacy stores. The outreach campaign will also involve in-store brochure displays and online insurance information and tools at CVS.com/insurance. Additionally, CVS Health is releasing new data that provides an initial look at prescription drug utilization by patients newly insured under the ACA. This data examines the population enrolled and how they are using their health insurance coverage, offering valuable insights for consumers, insurers and other stakeholders as they prepare for this year's open enrollment.
CVS: 89.80 (+0.67)

MinuteClinic Opens Its First Walk-in Medical Clinics in Wisconsin
PR Newswire - Thu Nov 13, 7:00AM CST
The first MinuteClinic walk-in medical clinics have opened in Wisconsin inside four CVS/pharmacy stores in Milwaukee, Menomonee Falls and Waukesha. MinuteClinic, the retail medical clinic of CVS Health, is the largest and fastest growing provider of walk-in clinics in the U.S, with locations in 31 states and the District of Columbia.
CVS: 89.80 (+0.67)

Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST

WDFC: 76.08 (-0.20), SJR: 26.81 (-0.01), PRGO: 154.73 (+0.27), XYL: 37.64 (+0.02), CHRW: 72.80 (-0.27), MDLZ: 38.12 (-0.04), MKC: 72.49 (-0.05), MDU: 25.14 (+0.05), SYY: 38.92 (+0.34), PDCO: 46.30 (+1.06), PNR: 69.22 (+0.56), TRI: 38.60 (+0.17), UPS: 106.32 (-0.51), PEP: 98.21 (+0.49), AGN: 208.77 (+10.12), MSI: 65.27 (+0.02), NOV: 71.83 (+0.49), NWN: 46.32 (+0.19), EGN: 66.44 (-1.52), EBAY: 54.99 (+0.63), QCOM: 70.61 (-0.24), AMAT: 22.53 (-0.29), ACN: 84.57 (-0.07), AAPL: 113.96 (-0.22), MA: 83.39 (-0.66), SCHW: 28.57 (-0.30), STR: 23.40 (+0.03), SE: 38.40 (+0.28), GAS: 52.16 (+0.71), IRM: 37.86 (+0.17), WM: 49.08 (-0.01), CMP: 88.84 (+0.01), VRSK: 63.00 (+0.13), GILD: 100.48 (-1.58), EXPD: 43.81 (-0.11), TFX: 115.37 (+0.54), CVS: 89.80 (+0.67), PG: 87.59 (-0.52), PX: 126.18 (+0.32), NVS: 94.46 (+0.51)

A Check-Up On The Earnings Of CVS Health
David Schauber, Jr. - at Seeking Alpha - Wed Nov 12, 4:08AM CST

CVS: 89.80 (+0.67)

Next Resistance Level for CVS Caremark (CVS) is $90.06
Comtex SmarTrend(R) - Tue Nov 11, 9:34AM CST
CVS Caremark (NYSE:CVS) has opened bullishly above the pivot of $88.77 today and has reached the first level of resistance at $89.63. Investors may be interested in a cross of the next upside pivot targets of $90.06 and $91.35.
CVS: 89.80 (+0.67)

3 Stocks Raising The Services Sector Higher
at The Street - Mon Nov 10, 11:08AM CST
TheStreet highlights 3 stocks pushing the health care sector higher today.
CVS: 89.80 (+0.67), WAG: 66.32 (-0.61), UNP: 120.45 (-0.26)

Hess Corporation Tops Best Value Long-Term Bond Ranking
Donald van Deventer - at Seeking Alpha - Sun Nov 09, 8:58AM CST

PSX: 72.81 (+1.03), SCCO: 30.42 (-0.11), SWY: 34.73 (-0.12), HES: 81.30 (-1.73), UTX: 107.61 (+0.16), RTN: 103.09 (-1.54), WMT: 83.56 (+0.60), TAP: 77.32 (+1.84), AMGN: 159.15 (+1.47), COP: 71.40 (-0.01), SWK: 95.39 (-0.28), DO: 36.39 (+0.58), IBM: 164.72 (+0.56), CVS: 89.80 (+0.67), CAT: 101.73 (+0.39), PPG: 205.62 (+1.72), WAG: 66.32 (-0.61)

Is CVS Health's "Tobacco-Tax" Brilliant or Stupid?
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 09, 8:44AM CST
Source: CVS Health Supporters are heralding CVS Health 's decision to create narrow pharmacy networks that penalize tobacco users as a brilliant move, but detractors think it may alienate customers. Both sides have valid arguments, but I...
ESRX: 78.74 (+0.87), CTRX: 49.35 (+0.91), MCK: 204.82 (-0.43), CVS: 89.80 (+0.67), WAG: 66.32 (-0.61), RAD: 5.46 (-0.07)

Update: CVS Earnings Feel A Cigarette Burn, But How Badly?
The Specialist - at Seeking Alpha - Sun Nov 09, 3:37AM CST

CVS: 89.80 (+0.67), DG: 65.12 (+0.47)

Apple Should Keep Cruising
Orange Peel Investments - at Seeking Alpha - Sat Nov 08, 2:29PM CST

WFM: 47.64 (+0.53), CVS: 89.80 (+0.67), AAPL: 113.96 (-0.22), RAD: 5.46 (-0.07)

3 Things That Can Keep the Wind in Catamaran Corp.'s Sails
Keith Speights, The Motley Fool - Motley Fool - Sat Nov 08, 8:00AM CST
It's been a relatively rough year for Catamaran Corporation so far. Just a couple of weeks ago, the pharmacy benefits manager's stock was down more than 10% and even farther away from the highs seen in 2013. After a strong third-quarter earnings...
CI: 103.01 (+1.11), ESRX: 78.74 (+0.87), CTRX: 49.35 (+0.91), CVS: 89.80 (+0.67)

CVS Health Is Poised To Grow
Investing Tricks - at Seeking Alpha - Fri Nov 07, 7:42AM CST

CVS: 89.80 (+0.67)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Updated Category News Views 21

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

Continue Reading
Paradigm Therapeutics: A Beacon in Rare Diseases

Updated Category News Views 4

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Continue Reading
Partner Valuation Advisors Bolsters Team with Eichman

Updated Category News Views 7

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Continue Reading
Skiptown Expands in Georgia Amid Growing Demand

Updated Category News Views 24

With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...

Continue Reading
Think Tank Pushes for Bold Parkinson's Prevention Plan

Updated Category News Views 25

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

Continue Reading
Veterans Transitioning to Real Estate with Scholarships

Updated Category News Views 15

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Continue Reading
Special Needs Group Partners with MAST to Enhance Accessibility

Updated Category News Views 22

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...

Continue Reading
Omneky Outshines Competitors in AI Ad Scoring

Updated Category News Views 33

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Continue Reading
New Data on SKYRIZI Offers Hope for Crohn's Patients

Updated Category News Views 16

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Continue Reading
Honeywell Aerospace Faces Legal Turbulence in Fraud Case

Updated Category News Views 7

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Continue Reading

Top 5 Most Recently Viewed Articles

Pieridae Energy Limited Reports Strong Q3 2024 Performance

Updated Category News Views 58

Strong Financial and Operational Results from Pieridae Energy CALGARY, Alberta - Pieridae Energy Limited (“Pieridae” or the “Company”) (TSX: PEA) has announced its third quarter 2024 financial and operating results, showcasing an impressive production output and robust financial performance. The company achieved a production rate of 23,116 barrels of oil...

Continue Reading
Atea Pharmaceuticals Showcases Promising HCV Treatment Data

Updated Category News Views 136

Innovation in Hepatitis C Treatment by Atea Pharmaceuticals Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) has made a significant impact in the field of antiviral therapeutics through their ongoing research and development efforts. The company recently presented compelling data at The Liver Meeting 2024, highlighting the promising combination of bemnifosbuvir and ruzasvir for...

Continue Reading
Study Confirms Safety of Combined Eye Drops for Surgery Use

Updated Category News Views 172

Introduction to the Study A five-year pharmacovigilance study has confirmed the excellent safety profile of a fixed-dose combination eye drop developed by NTC. This eye drop combines an anti-inflammatory steroid and a quinolone antibiotic, designed for preventing and treating inflammation, as well as preventing infection after cataract surgery. Study Overview The findings...

Continue Reading
New Concerns Arise for Roblox Amid Allegations of Misreported Metrics

Updated Category News Views 203

Allegations Against Roblox: A Closer Look Roblox Corp (NYSE: RBLX) has recently come under fire after a report from Hindenburg Research highlighted potential discrepancies in its reported user metrics, leading to a notable decline in its stock prices. The gaming platform is being questioned for allegedly overstating its user metrics, including daily active users (DAUs)...

Continue Reading
uniQure N.V. Faces Investigation Amid Securities Fraud Concerns

Updated Category News Views 155

Understanding the uniQure N.V. Investigation Currently, uniQure N.V. is under investigation concerning possible violations of securities laws. This inquiry has raised significant concerns for shareholders and potential investors, driving many to seek assistance in understanding their rights moving forward. The investigation is being led by the DJS Law Group, an...

Continue Reading